Experimental vaccine for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental vaccine called YKYY031 for people with advanced solid tumors that have stopped responding to standard treatments. The vaccine aims to help your immune system fight cancer cells that carry specific markers. It may be an option if you have certain genetic markers and tumor proteins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have an advanced or metastatic solid tumor (like colorectal or pancreatic cancer) that has failed standard therapy.
- You must have the HLA-A*11:01 genetic marker (a blood test can check this).
- Your tumor must test positive for at least one of the specific tumor proteins targeted by the vaccine.
- You should be feeling relatively well (able to do light activities) and have a life expectancy of at least 3 months.
- You need at least one measurable tumor lesion (a tumor that can be seen on scans).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YK1101 for people with advanced solid tumors that have not responded to standard treatment. It targets a specific protein (MAGE-A4) on cancer cells and requires a matching genetic type called HLA-A*11:01.
This trial tests an experimental treatment called GK01, which uses your own immune cells (called tumor-infiltrating lymphocytes) that have been taken from your tumor, multiplied in a lab, and given back to you. It is for people with advanced solid tumors that have not responded to standard treatments, and aims to see if these cells can shrink your cancer.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
This trial tests a personalized vaccine made from “neoantigens” (tumor-specific targets) to help your immune system fight advanced, inoperable solid tumors. It may be an option if standard treatment didn’t work or you stopped it and your health is strong enough for trial treatment.
This trial tests a personalized mRNA vaccine (RH125) designed to train your immune system to attack your cancer. It is for people with advanced solid tumors that have not responded to standard treatments, and it aims to see if the vaccine is safe and helpful.
Hear when a new Malignant Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.